Sunday, April 18, 2021
Home Life Style Health & Fitness Antiviral Remdesivir Receives FDA Approval for COVID Treatment

Antiviral Remdesivir Receives FDA Approval for COVID Treatment

Antiviral drug Veklury (Remdesivir) becomes the first to receive FDA approval for COVID treatment

The US Food and Drug Administration has approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.

Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval.

This approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020. The FDA granted approval and reissued the revised EUA to Gilead Sciences Inc.

Follow NewsGram on LinkedIn to know what’s happening around the world.

In order to ensure continued access to the pediatric population previously covered under the EUA, the FDA revised the EUA for Veklury to authorize the drug’s use for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. Clinical trials assessing the safety and efficacy of Veklury in this pediatric patient population are ongoing.

“The FDA is committed to expediting the development and availability of COVID-19 treatments during this unprecedented public health emergency,” said FDA Commissioner Stephen M. Hahn.

Antiviral Remdesivir
This approval does not include the entire population that had been authorized to use Remdesivir under an Emergency Use Authorization (EUA). Pixabay

“Today’s approval is supported by data from multiple clinical trials that the agency has rigorously assessed and represents an important scientific milestone in the COVID-19 pandemic. As part of the FDA’s Coronovarus Treatment Acceleration Programme, the agency will continue to help move new medical products to patients as soon as possible, while at the same time determining whether they are effective and if their benefits outweigh their risks.”

Under the Federal Food, Drug, and Cosmetic Act, approval of a new drug product requires substantial evidence of effectiveness and a demonstration of safety for the drug’s intended use(s). In considering the approval of a drug, the FDA conducts a benefit-risk assessment based on rigorous scientific standards to ensure that the product’s benefits outweigh its risks for the intended population.

Follow NewsGram on Facebook to stay updated.

The approval of Veklury was supported by the agency’s analysis of data from three randomized, controlled clinical trials that included patients hospitalized with mild-to-severe COVID-19.

One randomized, double-blind, placebo-controlled clinical trial (ACTT-1), conducted by the National Institute of Allergy and Infectious Diseases, evaluated how long it took for subjects to recover from COVID-19 within 29 days of being treated.

Follow NewsGram on Instagram to keep yourself updated.

The trial looked at 1,062 hospitalized subjects with mild, moderate, and severe COVID-19 who received Veklury or placebo, plus standard of care.

Recovery was defined as either being discharged from the hospital or being hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care.

Antiviral Remdesivir
Possible side effects include increased levels of liver enzymes, which may be a sign of liver injury; and allergic reactions, which may include changes in blood pressure and heart rate, low blood oxygen level, fever, shortness of breath, wheezing, swelling (e.g., lips, around eyes, under the skin), rash, nausea, sweating or shivering. Pixabay

The median time to recovery from COVID-19 was 10 days for the Veklury group compared to 15 days for the placebo group, a statistically significant difference. Overall, the odds of clinical improvement at Day 15 were also statistically significantly higher in the Veklury group when compared to the placebo group.

A second randomized, open-label multi-center clinical of hospitalized adult subjects with moderate COVID-19 compared treatment with Veklury for five days and treatment with Veklury for 10 days with the standard of care.

Want to read more in Hindi? Checkout: भारत के गलत मानचित्र को लेकर सरकार ने ट्विटर को दी चेतावनी.

Researchers evaluated the clinical status of subjects on Day 11. Overall, the odds of a subject’s COVID-19 symptoms improving were statistically significantly higher in the five-day Veklury group on Day 11 when compared to those receiving only standard of care. The odds of improvement with the 10-day treatment group, when compared to those receiving only standard of care, were numerically favorable, but not statistically significantly different.

A third separate, randomized, open-label multi-center clinical trial of hospitalized adult subjects with severe COVID-19 compared treatment with Veklury for five days and treatment with Veklury for 10 days.

Researchers evaluated the clinical status of subjects on Day 14. Overall, the odds of a subject’s COVID-19 symptoms improving were similar for those in the five-day Veklury group as those in the 10-day Veklury group, and there were no statistically significant differences in recovery rates or mortality rates between the two groups.

Also Read: Immediate Biomedical Waste Management Halts COVID Spread: UNIDO

Possible side effects include increased levels of liver enzymes, which may be a sign of liver injury; and allergic reactions, which may include changes in blood pressure and heart rate, low blood oxygen level, fever, shortness of breath, wheezing, swelling (e.g., lips, around eyes, under the skin), rash, nausea, sweating or shivering. (IANS)

STAY CONNECTED

19,517FansLike
362FollowersFollow
1,773FollowersFollow

Most Popular

Older Adults More Willing To Help Others As Compared To Younger Adults

New research has found that older adults are more willing to make an effort to help others as compared to younger adults. According to...

Explore The Heritage Of Punjab Through The Lens Of Documentary ‘The Bathinda Fort’

With a view to inspire the younger generation about the glorious historical and cultural heritage of Punjab, senior Advisor to Chief Minister Lt Gen...

Know About The Six Nepali Women Creating A Record Feat

Six Nepali women have reached the top of Mt. Annapurna creating a record feat on the 8,091-metre tall peak, the Himalayan nation's Department of...

Study: Covid19 Likely Not To Effect The Brain Directly

SARS-CoV-2, the virus that causes Covid-19, likely does not directly infect the brain but can still inflict significant neurological damage, a new study suggests....

Explained: The Connection Between Hindus And Yazidis

BY- JAYA CHOUDHARY The Yezidis are the Kurdish religious minorities from countries like Iraq, Syria, Iran, and Turkey. With the news focusing on the culture...

Spiritual Power To Guard, ‘Jai Shri Ram’ Printed Mask More In Demand

As the second wave of covid19 is increasing everywhere especially in Maharashtra and other states. The only possible way to protect yourself is to...

Close Representation Of Women And Men Competing For The First Time In History

UN Women, a United Nations entity for gender equality and women's empowerment, on Friday said that the 2021 Tokyo Olympics will have close to...

What Has Happened To Basic Cricket Intelligence?

The Indian Premier League (IPL) has commenced with a flourish. Cricket has become the entertainment in this scary, dreary, and home-bound alternative that one...

Recent Comments